drugset
drugset / Trial / NCT04157686

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

NCT04157686 ↗

Phase 3 Completed 957 enrolled Medy-Tox
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the long-term safety of MT10109L in the treatment of GL and/or LCL in participants with moderate to severe GL and/or LCL.

Timeline

Start
2019-10-23
Primary completion
2023-02-16
Completion
2023-02-16

Drugs

EvaluationDrugModalityDoseRoute
Subject NivobotulinumtoxinA Protein / enzyme biologic — Other

Indications

No indication recorded.